Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 16 de 16
Filter
Add more filters










Publication year range
2.
J Med Genet ; 42(6): e37, 2005 Jun.
Article in English | MEDLINE | ID: mdl-15937077

ABSTRACT

BACKGROUND: Gaucher disease is classified into neuronopathic and non-neuronopathic forms with wide phenotypic variation among patients sharing the same genotype. While homozygosity for the common L444P allele usually correlates with the neuronopathic forms, how a defined genotype leads to a phenotype remains unknown. METHODS: The genetic and epigenetic factors causing phenotypic differences were approached by a clinical association study in 32 children homozygous for the point mutation L444P. Direct sequencing and Southern blots were utilised to establish the genotype and exclude recombinant alleles. Glucocerebrosidase activity was measured in lymphoblast and fibroblast cell lines. RESULTS: Residual enzyme activity was highly variable and did not correlate with the observed clinical course. There was also a wide spectrum of phenotypes. Average age at diagnosis was 15 months, and slowed saccadic eye movements were the most prevalent finding. The most severe systemic complications and highest mortality occurred in splenectomised patients before the advent of enzyme replacement therapy (ERT). On ERT, as morbidity and mortality decreased, developmental and language deficits emerged as a major issue. Some trends related to ethnic background were observed. CONCLUSION: The wide clinical spectrum observed in the L444P homozygotes implicates the contribution of genetic modifiers in defining the phenotype in Gaucher disease.


Subject(s)
Gaucher Disease/diagnosis , Gaucher Disease/genetics , Glucosylceramidase/genetics , Child, Preschool , Female , Genotype , Glucosylceramidase/metabolism , Homozygote , Humans , Infant , Male , Phenotype , Point Mutation
3.
Hum Mutat ; 19(4): 458-9, 2002 Apr.
Article in English | MEDLINE | ID: mdl-11933202

ABSTRACT

Mutations in the gene encoding for the lysosomal enzyme glucocerebrosidase (GBA) result in Gaucher disease. In this study, seven novel missense mutations in the glucocerebrosidase gene (A136E, H162P, K198E, Y205C, F251L, Q350X and I402F) and a splice site mutation (IVS10+2T-->A) were identified by direct sequencing of three amplified segments of the glucocerebrosidase gene. Five of the novel mutations were found in patients with neuronopathic forms of Gaucher disease, two of which, K198E and F251L, appear to be associated with type 2 Gaucher disease.


Subject(s)
Gaucher Disease/genetics , Glucosylceramidase/genetics , Mutation, Missense/genetics , RNA Splice Sites/genetics , Alleles , Consanguinity , DNA Mutational Analysis , Ethnicity/genetics , Exons/genetics , Gaucher Disease/classification , Humans , Racial Groups/genetics
4.
Clin Genet ; 61(1): 32-4, 2002 Jan.
Article in English | MEDLINE | ID: mdl-11903352

ABSTRACT

Gaucher disease is caused by mutations in the gene for human glucocerebrosidase, a lysosomal enzyme involved in the intracellular hydrolysis of glucosylceramide. While over 150 different glucocerebrosidase mutations have been identified in patients with Gaucher disease, not all reported mutations have been fully characterized as being causative. One such mutation is the E326K mutation, which results from a G to A nucleotide substitution at genomic position 6195 and has been identified in patients with type 1, type 2 and type 3 Gaucher disease. However, in each instance, the E326K mutation was found on the same allele with another glucocerebrosidase mutation. Utilizing polymerase chain reaction (PCR) screening and restriction digestions of both patients with Gaucher disease and normal controls, we identified the E326K allele in both groups. Of the 310 alleles screened from patients with Gaucher disease, the E326K mutation was detected in four alleles (1.3%). In addition, screening for the E326K mutation among normal controls from a random population revealed that three alleles among 316 screened (0.9%) also carried the E326K mutation. In the normal controls with the E326K allele, the glucocerebrosidase gene was completely sequenced, but no additional mutations were found. Because the E326K mutation may be a polymorphism, we caution that a careful examination of any allele with this mutation should be performed to check for the presence of other glucocerebrosidase mutations.


Subject(s)
Gaucher Disease/genetics , Glucosylceramidase/genetics , Mutation, Missense/genetics , Polymorphism, Genetic/genetics , Alleles , Case-Control Studies , Cells, Cultured , DNA Mutational Analysis , Female , Gaucher Disease/enzymology , Glucosylceramidase/chemistry , Humans , Male
5.
Mol Genet Metab ; 73(4): 313-21, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11509013

ABSTRACT

Among the many phenotypes associated with Gaucher disease, the inherited deficiency of glucocerebrosidase, are reports of patients with parkinsonian symptoms. The basis for this association is unknown, but could be due to alterations in the gene or gene region. The human glucocerebrosidase gene, located on chromosome 1q21, has a nearby pseudogene that shares 96% identity. Immediately adjacent to the glucocerebrosidase pseudogene is a convergently transcribed gene, metaxin, which has a pseudogene that is located just downstream to the glucocerebrosidase gene. We describe a patient with mild Gaucher disease but impaired horizontal saccadic eye movements who developed a tremor at age 42, followed by rapid deterioration of her gait. A pallidotomy at age 47 was unsuccessful. Her motor and cognitive deterioration progressed despite enzyme replacement therapy. Sequencing of the glucocerebrosidase gene identified mutations L444P and D409H. Southern blot analysis using the enzyme SspI showed that the maternal allele had an additional 17-kb band. PCR amplifications and sequencing of this fragment demonstrated a duplication which included the glucocerebrosidase pseudogene, metaxin gene, and a pseudometaxin/metaxin fusion. Gene alterations associated with this novel rearrangement, resulting from a crossover between the gene for metaxin and its pseudogene, could contribute to the atypical phenotype encountered in this patient.


Subject(s)
Gaucher Disease/genetics , Gaucher Disease/physiopathology , Glucosylceramidase/genetics , Parkinson Disease, Secondary/complications , Parkinson Disease, Secondary/genetics , Ubiquitin-Protein Ligases , Alleles , Blotting, Southern , Chromosomes, Human, Pair 1/genetics , Crossing Over, Genetic/genetics , DNA Mutational Analysis , Female , Gaucher Disease/enzymology , Gaucher Disease/therapy , Genotype , Glucosylceramidase/deficiency , Glucosylceramidase/metabolism , Glucosylceramidase/therapeutic use , Humans , In Situ Hybridization, Fluorescence , Ligases/genetics , Male , Middle Aged , Mitochondrial Membrane Transport Proteins , Nerve Tissue Proteins/genetics , Parkinson Disease, Secondary/enzymology , Parkinson Disease, Secondary/physiopathology , Phenotype , Physical Chromosome Mapping , Polymorphism, Genetic/genetics , Proteins/genetics , Pseudogenes/genetics , RNA, Messenger/analysis , RNA, Messenger/genetics , Synucleins
6.
Mol Genet Metab ; 63(4): 281-8, 1998 Apr.
Article in English | MEDLINE | ID: mdl-9635296

ABSTRACT

Gaucher disease, the deficiency of the lysosomal enzyme glucocerebrosidase (EC 3.2.1.45), is frequently encountered in the Ashkenazi Jewish population. Carrier screening for Gaucher disease by enzyme analysis performed during a routine pregnancy indicated that both Ashkenazi parents were carriers. Screening for four common Gaucher mutations was subsequently performed on fetal and parental DNA. None of the common Ashkenazi mutations were identified. However, when exons 9-11 were amplified and digested with NciI to detect the L444P mutation, it appeared that the mother and the fetus had an unusual allele and that the expected paternal allele was not present. When the fetal amniocytes were found to have less than 2% of the normal glucocerebrosidase activity and a fetal sonogram revealed hydrops fetalis, the pregnancy was terminated. The diagnosis of severe type 2 Gaucher disease was confirmed at autopsy. Ultrastructural studies of epidermis from the fetus revealed the characteristic disruption of lamellar bilayers, diagnostic for type 2 Gaucher disease. In subsequent studies of the fetal DNA, long-template polymerase chain reaction amplification revealed one appropriately sized band (approximately 6.5 kb) and one smaller (approximately 5.2 kb) band. Sequencing of the approximately 5.2-kb fragment identified a novel fusion allele resulting from recombination between the glucocerebrosidase gene and its pseudogene beginning in intron 3. This fusion allele was inherited from the father. The result was confirmed by Southern blot analysis using the enzyme S8tII. Sequencing of the 6.5-kb fragment identified a previously described, although rare, T-to-G splice junction mutation in intron 10 of the maternal allele, which introduced an NciI site. The couple had a subsequent pregnancy which was also found to be affected. This case study identifies a novel recombinant allele and an unusual splice junction mutation, and demonstrates that even in the Ashkenazi population, screening for common mutations may not accurately identify the most severe forms of the disease.


Subject(s)
Alleles , Alternative Splicing/genetics , Gaucher Disease/genetics , Glucosylceramidase/genetics , Hydrops Fetalis/genetics , Point Mutation , Base Sequence , Female , Humans , Jews/genetics , Male , Molecular Sequence Data , Polymerase Chain Reaction , Pregnancy , Prenatal Diagnosis , Recombination, Genetic
7.
Pediatr Res ; 43(5): 571-8, 1998 May.
Article in English | MEDLINE | ID: mdl-9585001

ABSTRACT

Gaucher's disease, the inherited deficiency of glucocerebrosidase, manifests with vast phenotypic variation. Even among patients with type 2 (acute neuronopathic) Gaucher's disease, there is a spectrum of clinical presentations. DNA samples from 14 patients with type 2 Gaucher's disease with a course ranging from intrauterine death at 22 wk of gestation to survival until age 30 mo were studied. L444P was the only common mutation identified, found in 15 patients' alleles. Sequencing of genomic DNA amplified by long template PCR revealed that mutation L444P occurred as a single point mutation in seven mutant alleles and as part of a recombinant allele in eight mutant alleles. Two patients had a deletion of 55 bp in exon 9; in one patient the deletion was part of a recombinant allele, and in a second the deletion occurred alone. Direct sequencing identified R120W on one allele, P415R on another, and one fetus was homoallelic for a deletion of a C nucleotide at codon 139 in exon 5. Eight of the mutant alleles remain unidentified. Northern blots revealed an appropriately sized mRNA in all except one of the patients studied. Of the 14 type 2 Gaucher patients, three had hydrops fetalis and died in utero or at birth, five had congenital ichthyosis, and seven survived 5 mo or more. Patients who died in the neonatal period had decreased protein detected by Western blot, regardless of genotype observed. These studies demonstrate that genotypic heterogeneity exists in patients with type 2 Gaucher's disease, even among infants with the most severe phenotypes.


Subject(s)
Gaucher Disease/genetics , Genetic Variation , Glucosylceramidase/genetics , Point Mutation , Sequence Deletion , Abortion, Spontaneous/genetics , Alleles , Child, Preschool , Female , Fetal Death , Gaucher Disease/classification , Gaucher Disease/enzymology , Genotype , Humans , Infant , Infant, Newborn , Male , Phenotype , Polymerase Chain Reaction , Pregnancy , Recombination, Genetic
8.
Am J Med Genet ; 73(1): 41-7, 1997 Nov 28.
Article in English | MEDLINE | ID: mdl-9375921

ABSTRACT

The complete spectrum of clinical phenotypes resulting from glucocerebrosidase deficiency continues to evolve. While most patients with Gaucher disease have residual glucocerebrosidase activity, we describe a fetus with severe prenatal lethal type 2 (acute neuronopathic) Gaucher disease lacking glucocerebrosidase activity. This 22-week fetus was the result of a first cousin marriage and had hydrops, external abnormalities, hepatosplenomegaly, and Gaucher cells in several organs. Fetal fibroblast DNA was screened for common Gaucher mutations, none of which was detected. Southern blot analysis using the restriction enzymes SstII and SspI ruled out a fusion gene, deletion, or duplication of either allele, and quantitative studies of SspI digested genomic DNA indicated that both alleles were present. Northern blot analysis of total RNA from fetal fibroblasts demonstrated no detectable transcription, although RT-PCR successfully amplified several exons, suggesting the presence of a very unstable mRNA. Direct PCR sequencing of all exons demonstrated a homozygous frameshift mutation (deletion of a C) on codon 139 in exon 5, thereby introducing a premature termination codon in exon 6. The absence of glucocerebrosidase protein was confirmed by Western analysis. This unique case confirms the essential role of glucocerebrosidase in human development and, like the null allele Gaucher mouse, demonstrates the lethality of a homozygous null mutation. The presence of this novel mutation and the resulting unstable mRNA accounts for the severity of the phenotype observed in this fetus, and contributes to the understanding of genotype/phenotype correlation in Gaucher disease.


Subject(s)
Fetal Death , Gaucher Disease/enzymology , Gene Deletion , Glucosylceramidase/genetics , Homozygote , Blotting, Southern , Blotting, Western , Exons , Female , Frameshift Mutation , Gaucher Disease/embryology , Gaucher Disease/genetics , Gaucher Disease/mortality , Glucosylceramidase/metabolism , Humans , Male , Pedigree , Polymerase Chain Reaction , Pregnancy
9.
J Med Genet ; 33(2): 132-6, 1996 Feb.
Article in English | MEDLINE | ID: mdl-8929950

ABSTRACT

It has recently been emphasised that a subset of patients with type 2 Gaucher disease die in the neonatal period. This report describes an Afghani family with two conceptuses having severe, prenatally detected Gaucher disease. Mutational analysis showed that the family carried a known complex allele which included mutations at amino acids L444P, A456P, and V460V. Although glucocerebrosidase RNA was present, an affected fetus had virtually no glucocerebrosidase cross reactive material on western analyses. The severe clinical course and pathology observed in these patients resemble that of the null allele Gaucher mouse, and suggest that the absence of glucocerebrosidase activity results in early death.


Subject(s)
Gaucher Disease/genetics , Glucosylceramidase/deficiency , Afghanistan/ethnology , Alleles , Animals , Base Sequence , Cells, Cultured , DNA Mutational Analysis , Fatal Outcome , Fibroblasts/enzymology , Fibroblasts/pathology , Gaucher Disease/classification , Gaucher Disease/enzymology , Gaucher Disease/pathology , Genes, Lethal , Genes, Recessive , Glucosylceramidase/genetics , Humans , Infant, Newborn , Male , Mice , Mice, Knockout , Molecular Sequence Data , Phenotype
11.
Nature ; 357(6377): 407-10, 1992 Jun 04.
Article in English | MEDLINE | ID: mdl-1594045

ABSTRACT

Gaucher's disease is the most prevalent lysosomal storage disorder in humans and results from an autosomally inherited deficiency of the enzyme glucocerebrosidase (beta-D-glucosyl-N-acylsphingosine glucohydrolase), which is responsible for degrading the sphingolipid glucocerebroside. An animal model for Gaucher's disease would be important for investigating its phenotypic diversity and pathogenesis and for evaluating therapeutic approaches. A naturally occurring canine model has been reported but not propagated. Attempts to mimic the disease in animals by inhibiting glucocerebrosidase have been inadequate. Here we generate an animal model for Gaucher's disease by creating a null allele in embryonic stem cells through gene targeting and using these genetically modified cells to establish a mouse strain carrying the mutation. Mice homozygous for this mutation have less than 4% of normal glucocerebrosidase activity, die within twenty-four hours of birth and store glucocerebroside in lysosomes of cells of the reticuloendothelial system.


Subject(s)
Disease Models, Animal , Gaucher Disease/genetics , Glucosylceramidase/genetics , Animals , Bone Marrow/metabolism , Bone Marrow/pathology , Brain/metabolism , Brain/ultrastructure , Female , Gaucher Disease/pathology , Gaucher Disease/physiopathology , Glucosylceramidase/deficiency , Homozygote , Lipid Metabolism , Liver/metabolism , Liver/ultrastructure , Lysosomes/metabolism , Male , Mice , Mice, Transgenic , Microscopy, Electron , Mutation , Spleen/metabolism , Spleen/ultrastructure
12.
Clin Genet ; 41(1): 1-5, 1992 Jan.
Article in English | MEDLINE | ID: mdl-1633639

ABSTRACT

Sixteen non-Ashkenazic American children with Gaucher disease who demonstrate slowing of the horizontal saccades are described. Attempts to correlate this specific clinical phenotype with a unique genotype were unsuccessful. Focusing on the three most common mutations, at least five different genotypes were present in these patients. Children with this isolated oculomotor abnormality generally had a diffusely slowed background on EEG, but an otherwise normal neurologic examination, and exhibited earlier and more severe systemic manifestations and mortality. This study emphasizes the need for careful sequential neuro-ophthalmologic examinations in Gaucher patients and the need for caution in attempting to make clinical predictions regarding the course of Gaucher disease on the basis of current DNA mutational analysis.


Subject(s)
Gaucher Disease/genetics , Ocular Motility Disorders/genetics , Saccades , Adolescent , Alleles , Base Sequence , Child , Child, Preschool , DNA Mutational Analysis , Electroencephalography , Female , Gaucher Disease/complications , Gaucher Disease/ethnology , Gaucher Disease/physiopathology , Genotype , Humans , Infant , Male , Molecular Sequence Data , Phenotype
13.
J Neurochem ; 51(5): 1651-4, 1988 Nov.
Article in English | MEDLINE | ID: mdl-2844998

ABSTRACT

A human cDNA clone containing the 5' coding region of the GABAA/benzodiazepine receptor alpha subunit was used to quantify and visualize receptor mRNA in various regions of the rat brain. Using a [32P]CTP-labelled antisense RNA probe (860 bases) prepared from the alpha subunit cDNA, multiple mRNA species were detected in Northern blots using total and poly A rat brain RNA. In all brain regions, mRNAs of 4.4 and 4.8 kb were observed, and an additional mRNA of 3.0 kb was detected in the cerebellum and hippocampus. The level of GABAA/benzodiazepine receptor mRNA was highest in the cerebellum followed by the thalamus = frontal cortex = hippocampus = parietal cortex = hypothalamus much greater than pons = striatum = medulla. In situ hybridization revealed high levels of alpha subunit mRNA in cerebellar gray matter, olfactory bulb, thalamus, hippocampus/dentate gyrus, and the arcuate nucleus of the hypothalamus. These data suggest the presence of multiple GABAA/benzodiazepine receptor alpha subunit mRNAs in rat brain and demonstrate the feasibility of studying the expression of genes encoding the GABAA/benzodiazepine receptor after pharmacological and/or environmental manipulation.


Subject(s)
Brain Chemistry , RNA, Messenger/analysis , Receptors, GABA-A/genetics , Animals , Blotting, Northern , Cerebellum/analysis , Cerebral Cortex/analysis , Hippocampus/analysis , Hypothalamus/analysis , Male , Nucleic Acid Hybridization , RNA Probes , Rats , Rats, Inbred Strains , Thalamus/analysis , Tissue Distribution
15.
Proc Natl Acad Sci U S A ; 85(7): 2349-52, 1988 Apr.
Article in English | MEDLINE | ID: mdl-3353383

ABSTRACT

Nucleotide sequence analysis of a genomic clone from an Ashkenazic Jewish patient with type 1 Gaucher disease revealed a single-base mutation (adenosine to guanosine transition) in exon 9 of the glucocerebrosidase gene. This change results in the amino acid substitution of serine for asparagine. Transient expression studies following oligonucleotide-directed mutagenesis of the normal cDNA confirmed that the mutation results in loss of glucocerebrosidase activity. Allele-specific hybridization with oligonucleotide probes demonstrated that this mutation was found exclusively in the type 1 phenotype. None of the 6 type 2 patients, 11 type 3 patients, or 12 normal controls had this allele. In contrast, 15 of 24 type 1 patients had one allele with this mutation, and 3 others were homozygous for the mutation. Furthermore, some of the Ashkenazic Jewish type 1 patients had only one allele with this mutation, suggesting that even in this population there is allelic heterozygosity. These findings indicate that there are multiple allelic mutations responsible for type 1 Gaucher disease in both the Jewish and non-Jewish populations. Allelic-specific hybridization demonstrating this mutation in exon 9, used in conjunction with the Nci I restriction fragment length polymorphism described as a marker for neuronopathic Gaucher disease, provides a tool for diagnosis and genetic counseling that is approximately equal to 80% informative in all Gaucher patients studied.


Subject(s)
Gaucher Disease/genetics , Glucosidases/genetics , Glucosylceramidase/genetics , Jews , Adolescent , Adult , Alleles , Amino Acid Sequence , Base Sequence , Child , Child, Preschool , Gaucher Disease/classification , Gaucher Disease/enzymology , Genotype , Glucosylceramidase/deficiency , Humans , Infant , Middle Aged , Molecular Sequence Data , Mutation , Risk
16.
N Engl J Med ; 316(10): 570-5, 1987 Mar 05.
Article in English | MEDLINE | ID: mdl-2880291

ABSTRACT

To search for a genetic marker for type 2 Gaucher's disease (acute neuronopathic form), we compared the nucleotide sequence of a cloned glucocerebrosidase gene from a patient with Gaucher's disease with a normal gene. We found only a single base substitution (T----C) in exon X. This mutation results in the substitution of proline for leucine in position number 444 and produces a new cleavage site for the NciI restriction endonuclease. We analyzed NciI enzymatic digests of genomic DNA from 20 patients with type 1, 5 with type 2, and 11 with type 3 Gaucher's disease, and 29 normal controls for a restriction-fragment-length polymorphism (RFLP). Four of 5 patients with type 2 disease and all 11 with type 3 disease had at least one allele with the mutation. Two of 5 patients with type 2 disease and 7 of 11 with type 3 were homozygous for this mutation. Only 4 of 20 patients with type 1 Gaucher's disease had the mutant allele and were heterozygous for it. None of the 29 normal controls had the mutant allele. The high frequency of this mutation (444leucine----proline) in patients with neuronopathic Gaucher's disease, detectable by the NciI RFLP, may be of value in the identification of patients who will have the neurologic sequelae of Gaucher's disease.


Subject(s)
Gaucher Disease/genetics , Glucosidases/genetics , Glucosylceramidase/genetics , Mutation , Adolescent , Adult , Alleles , Base Sequence , Child , Exons , Humans , Middle Aged , Nervous System Diseases/genetics , Polymorphism, Restriction Fragment Length
SELECTION OF CITATIONS
SEARCH DETAIL
...